circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X 20th Annual Needham Virtual Healthcare Conference
    Apr 12, 2021 3:00 PM EDT

    20th Annual Needham Virtual Healthcare Conference
    Apr 12, 2021 3:00 PM EDT
  • Webcast
    X Barclays Global Healthcare Conference
    Mar 11, 2021 9:45 AM EST

    Barclays Global Healthcare Conference
    Mar 11, 2021 9:45 AM EST
  • Webcast
    X H.C. Wainwright Global Life Sciences Conference
    Mar 9, 2021 7:00 AM EST

    H.C. Wainwright Global Life Sciences Conference
    Mar 9, 2021 7:00 AM EST

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the American Chemical Society Spring 2021 Virtual Meeting
Next-In-Class Cardiac Myosin Inhibitor Optimized for Shallow Exposure Response and Pharmacokinetics to Enable Flexible Dose Titration SOUTH SAN FRANCISCO, Calif. , April 12, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data related to the optimization of
Toggle Summary Cytokinetics to Participate in the 20th Annual Needham Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , April 05, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the 20 th Annual Needham Virtual Healthcare Conference on
Toggle Summary Cytokinetics Announces Preclinical Data for CK-3773274 to be Presented at the American Chemical Society Spring 2021 Virtual Meeting
SOUTH SAN FRANCISCO, Calif. , April 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data relating to CK-3773274 (CK-274), including data regarding its discovery and key optimization parameters, will be presented at the American Chemical Society Spring
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , April 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 31, 2021 it granted stock options to purchase an aggregate of 163,700 shares of common stock to three new employees, whose employment commenced in March 2021 , as

EVENTS

There are currently no events to display.